Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (671-680 of 993) with videos related to

Pageof 100
Sort By:
European Urology Oncology|November 4, 2024
Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel TrialAndrew J Armstrong, Noel Clarke, Mototsugu Oya, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)Fred Saad, Kim N Chi, Neal D Shore, et al.
The Prostate|April 2, 2022
Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidatesGabriele Sorce, Rocco Simone Flammia, Benedikt Hoeh, et al.
The New England Journal of Medicine|May 30, 2020
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate CancerCora N Sternberg, Karim Fizazi, Fred Saad, et al.
The Journal of Urology|January 4, 2014
The health care burden of skeletal related events in patients with renal cell carcinoma and bone metastasisCarina Antczak, Vincent Q Trinh, Akshay Sood, et al.
BJU International|November 15, 2012
Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract CollaborationAdrian S Fairey, Wassim Kassouf, Eric Estey, et al.
The Journal of Urology|July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN TrialSoumyajit Roy, Yilun Sun, Kim N Chi, et al.
The Prostate|March 15, 2023
The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapyFrancesco Chierigo, Rocco Simone Flammia, Gabriele Sorce, et al.
Annals of Surgical Oncology|February 27, 2026
Type 2 Diabetes Mellitus Versus Adverse In-Hospital Outcomes After Partial or Radical NephrectomyMaximilian Filzmayer, Michele Nicolazzini, Calogero Catanzaro, et al.
BMJ Open|May 28, 2026
Cohort profile: BioCaPPE (Biomarkers of Prostate Cancer/Prevention and Environment) - a Canadian multicentre prospective study of lifestyle and candidate biomarkers in relation to prostate cancer riskHanane Moussa, Roxane Tourigny, Karine Robitaille, et al.
Pageof 100

Showing results (671-680 of 993) with videos related to

Sort By:
Pageof 100
European Urology Oncology|November 4, 2024
Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel TrialAndrew J Armstrong, Noel Clarke, Mototsugu Oya, et al.
Cancer Chemotherapy and Pharmacology|March 23, 2021
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)Fred Saad, Kim N Chi, Neal D Shore, et al.
The Prostate|April 2, 2022
Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidatesGabriele Sorce, Rocco Simone Flammia, Benedikt Hoeh, et al.
The New England Journal of Medicine|May 30, 2020
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate CancerCora N Sternberg, Karim Fizazi, Fred Saad, et al.
The Journal of Urology|January 4, 2014
The health care burden of skeletal related events in patients with renal cell carcinoma and bone metastasisCarina Antczak, Vincent Q Trinh, Akshay Sood, et al.
BJU International|November 15, 2012
Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract CollaborationAdrian S Fairey, Wassim Kassouf, Eric Estey, et al.
The Journal of Urology|July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN TrialSoumyajit Roy, Yilun Sun, Kim N Chi, et al.
The Prostate|March 15, 2023
The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapyFrancesco Chierigo, Rocco Simone Flammia, Gabriele Sorce, et al.
Annals of Surgical Oncology|February 27, 2026
Type 2 Diabetes Mellitus Versus Adverse In-Hospital Outcomes After Partial or Radical NephrectomyMaximilian Filzmayer, Michele Nicolazzini, Calogero Catanzaro, et al.
BMJ Open|May 28, 2026
Cohort profile: BioCaPPE (Biomarkers of Prostate Cancer/Prevention and Environment) - a Canadian multicentre prospective study of lifestyle and candidate biomarkers in relation to prostate cancer riskHanane Moussa, Roxane Tourigny, Karine Robitaille, et al.
Pageof 100